



## MaxCyte to Participate in Upcoming Investor Conferences

May 3, 2022 8:05 PM EDT

GAITHERSBURG, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will participate in the following investor conferences:

- Bank of America 2022 Healthcare Conference  
Presentation on Wednesday, May 11<sup>th</sup> at 4:40 p.m. Pacific Time
- William Blair 42<sup>nd</sup> Annual Growth Stock conference  
Fireside chat on Wednesday, June 8<sup>th</sup> at 9:20 a.m. Central Time

Live and archived webcasts of the events will be available on the "Events" section of the MaxCyte investor relations website at <https://investors.maxcyte.com/>.

### About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™, and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

### MaxCyte Contacts:

#### **US IR Adviser**

Gilmartin Group  
David Deuchler, CFA

+1 415-937-5400  
[ir@maxcyte.com](mailto:ir@maxcyte.com)

#### **Nominated Adviser and Joint Corporate Broker**

Panmure Gordon  
Emma Earl / Freddy Crossley  
Corporate Broking  
Rupert Dearden

+44 (0)20 7886 2500

#### **UK IR Adviser**

Consilium Strategic Communications  
Mary-Jane Elliott  
Chris Welsh

+44 (0)203 709 5700  
[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)